07th week of 2010 patent applcation highlights part 44 |
Patent application number | Title | Published |
20100041666 | Use of N-Phenyl-2-pyrimidineamine Derivativea Against Mast Cell-based Diseases Like Allergic Disorders - Use of the N-phenyl-2-pyrimidine-amine derivatives of formula I, | 2010-02-18 |
20100041667 | Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease - The present invention is directed to compounds of formula (I) | 2010-02-18 |
20100041668 | Compositions and methods for treating thrombocytopenia - The present invention in certain embodiments is directed to a pharmaceutical dosage form comprising a therapeutically effective amount of a first agent that agonizes a human TPO receptor by binding to the rhTPO binding site of the human TPO receptor; and a therapeutically effective amount of a second agent that agonizes the human TPO receptor by binding to a binding site of the human TPO receptor distinct from the rhTPO binding site. | 2010-02-18 |
20100041669 | 4-(HETEROCYCLYL)ALKYL-N-(ARYLSULFONYL)INDOLE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS - Compounds including 4-(Heterocyclyl)alkyl-N-(arylsulfonyl)indole compounds of the formula (I), their derivatives, their stereoisomers, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them as well as a process for the preparation of these compounds, their derivatives, their stereoisomers, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them. These compounds are useful in the treatment of various disorders that are related to 5-HT | 2010-02-18 |
20100041670 | TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES AND TRIAZOLOPYRIMIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF - The invention relates to the triazolopyridine carboxamide derivatives and triazolopyrimidine carboxamide derivatives of general formula (I): | 2010-02-18 |
20100041671 | Methods for treating glaucoma - A method for treating glaucoma comprising administering to a patient pharmaceutically effective amounts of a Rho kinase inhibitor and a prostaglandin. | 2010-02-18 |
20100041672 | USE OF QUINOLINE DERIVATIVES IN THE TREATMENT OF PAIN AND IRRITABLE BOWEL SYNDROME - The use of 5-HT | 2010-02-18 |
20100041673 | 5-(HETEROCYCLYL)ALKYL-N-(ARYLSULFONYL)INDOLE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS - Compounds including 5-(Heterocyclyl)alkyl-N-(arylsulfonyl)indole, their derivatives, their stereoisomers, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them and a process for the preparation of these compounds, their derivatives, their stereoisomers, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them. These compounds are useful in the treatment of various disorders that are related to 5-HT6 receptor functions. Specifically, the compounds of this invention are also useful in the treatment of various CNS disorders, hematological disorders, eating disorders, diseases associated with pain, respiratory diseases, genito-urological disorders, cardiovascular diseases and cancer. | 2010-02-18 |
20100041674 | HCV PROTEASE INHIBITORS AND USES THEREOF - The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. | 2010-02-18 |
20100041675 | METHODS FOR THE USE OF PYRIMIDINE DERIVATIVES WHICH ARE ANTAGONISTS OF VITRONECTIN RECEPTOR - A subject of the invention is the compounds of formula (I); | 2010-02-18 |
20100041676 | Kinase inhibitors - The present application is directed to compounds of the formula (I) | 2010-02-18 |
20100041677 | INHIBITORS OF BRUTON'S TYROSINE KINASE - Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. | 2010-02-18 |
20100041678 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISORDERS - The present disclosure relates to methods of treating inflammatory disorders by administering a Syk inhibitory 2,4-pyrimidinediamine compound and a second agent. | 2010-02-18 |
20100041679 | ORAL DIETING COMPOSITION COMPRISING CONJUGATED LINOLEIC ACID AND CAFFEINE - The invention relates to a dieting composition for oral administration, comprising a mixture of conjugated linoleic acid and caffeine as active ingredient and an acceptable support for oral administration. | 2010-02-18 |
20100041680 | PIPERIDINE DERIVATIVES - Compounds of formula I: I selectively inhibit production of Ab(1-42) and hence find use in treatment of Alzheimer's disease and other conditions associated with deposition of A(b) in the brain. | 2010-02-18 |
20100041681 | 2-AMINO PYRIMIDINE COMPOUNDS AS POTENT HSP-90 INHIBITORS - The present invention is directed to compounds of formula (I), | 2010-02-18 |
20100041682 | Ternary Pesticidal Mixtures - Ternary pesticidal mixtures comprising, as active components, an anthranilamid compound of the formula (I) wherein the variables are defined according to the description, and two fungicidal compounds II and III selected from the following groups: azoles, strobilurins, carboxamides, heterocylic compounds, carbamates, guanidines, antibiotics, nitrophenyl derivates, sulfur-containing heterocyclyl compounds, organometal compounds and other active compounds according to the description, in a synergistically effective amount, methods for controlling pests, and harmful fungi, methods of protecting plants from attack or infestation by insects, acarids or nematodes, methods for treating, controlling, preventing or protecting an animal against infestation or infection by parasites, compositions containing these mixtures, and methods for their preparation. | 2010-02-18 |
20100041683 | NOVEL CHAIN-BREAKING ANTIOXIDANTS - Compounds, preferably 5-pyrimidinol and 3-pyridinol derivatives, that act as effective chain breaking antioxidants of both the lipid and water-soluble variety (analogous to the natural Vitamins E and C), many of which are more reactive toward peroxyl radicals than the most potent form of Vitamin E. These compounds may exhibit many chemopreventive effects associated with conditions in which free radical-mediated cellular damage or disruption is implicated and Vitamins E and C are shown to have protective effects. Additionally, these compounds should be excellent oxidation inhibitors as additives to fuels, lubricants, rubber, polymers, chemicals, solvents and foodstuffs. | 2010-02-18 |
20100041684 | PYRIMIDYL DERIVATIVES AS PROTEIN KINASE INHIBITORS - Objects of the present invention are the compounds of formula (I), their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above compounds, medicaments containing them and their manufacture, as well as the use of the above compounds in the control or prevention of illnesses such as cancer. | 2010-02-18 |
20100041685 | STAT3 INHIBITORS - Small molecule inhibitors of Stat3 and their derivatives are disclosed. Also described are methods to inhibit cell growth by use of Stat3 inhibitors, and the use of Stat3 inhibitors for the prevention and/or treatment of cancer. Further, inhibitors of Stat3 that also do not inhibit Stat1 are described as well as their derivatives. Methods of screening additional compounds for Stat3 inhibition activity and/or non-inhibition of Stat1 activity are also described herein. | 2010-02-18 |
20100041686 | 4,5-DIHYDRO-OXAZOL-2YL DERIVATIVES - The invention relates to compounds of formula I | 2010-02-18 |
20100041687 | HYDROBROMIDE SALT OF AN ANTI-HIV COMPOUND - Solid dispersions and dosage forms comprising the hydrobromide salt of a diarylpyrimidine derivative, useful as an anti-HIV agent. | 2010-02-18 |
20100041688 | REVAPRAZAN-CONTAINING SOLID DISPERSION AND PROCESS FOR THE PREPARATION THEREOF - The present invention provides a solid dispersion in which revaprazan particles are surface-modified with a water-soluble polymer, a water-soluble saccharide, a surfactant, or a mixture thereof and a process for preparing the same. The present invention also provides a pharmaceutical composition containing the solid dispersion and a process for preparing the pharmaceutical composition. | 2010-02-18 |
20100041689 | Combined Effects of Topiramate and Ondansetron on Alcohol Consumption - The present invention provides for the use of combinations of drugs to treat addictive disorders. More specifically, the present invention relates the use of drugs in conjunction with behavioral intervention to treat alcohol-related diseases and disorders as well as treatment of obesity and regulating weight. | 2010-02-18 |
20100041690 | Co-Administration of Dopamine-Receptor Binding Compounds - Methods for treating a patient having neurological, psychotic, and psychiatric disorders are described comprising the steps of administering to the patient an effective amount of a partial and/or full dopamine D | 2010-02-18 |
20100041691 | PHARMACEUTICAL COMPOSITIONS COMPRISING COMBINATIONS OF AN AMPA/KAINATE ANTAGONISTIC COMPOUND AND AN INHIBITOR OF A MULTIDRUG RESISTANCE PROTEIN - This invention relates to pharmaceutical compositions comprising a combination of an AMPA/kainate antagonistic compound and an inhibitor of a multidrug resistance protein and its use for combating epileptic disorders. | 2010-02-18 |
20100041692 | PYRROLO[4,3,2-DE]QUINOLIN-8-AMINE COMPOUNDS AND METHODS OF THEIR PREPARATION AND USE - The present invention relates to compounds of formula I: | 2010-02-18 |
20100041693 | INDOLYLMALEIMIDE DERIVATIVES - A compound of formula (I) | 2010-02-18 |
20100041694 | AGRICULTURAL COMPOSITION FOR CONTROLLING OR PREVENTING PLANT DISEASES CAUSED BY PLANT PATHOGENIC MICROBES - An agricultural composition comprising an amide compound represented by the following formula (I), | 2010-02-18 |
20100041695 | Thieno[2,3-b]pyridines as Potassium Channel Inhibitors - The invention provides compounds of the formula: | 2010-02-18 |
20100041696 | Compounds - The present invention relates to substituted 4-Aminopyrazole compounds of the formula (I): | 2010-02-18 |
20100041697 | PNEUMONIA TREATMENT - This invention relates to a method of treating pneumonia by orally administering to a subject in need thereof a quinolone compound of formula (I), shown in the disclosure, at a daily dose of 2-30 mg/kg. | 2010-02-18 |
20100041698 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS - The invention relates to compounds of general formula (I), corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof and the prodrugs of said compounds. The invention also relates to the use of said compounds as binding partners for 5-HT5 receptors for treating diseases that are modulated by a 5-HT5 receptor activity, in particular, for treating neurodegenerative and neuropsychiatric disorders as well as signs, symptoms and dysfunctions. | 2010-02-18 |
20100041699 | MICROCRYSTALLINE (5-FLUORO-2-METHYL-3-QUINOLIN-2-YLMETHYL-INDOL-1-YL) ACETIC ACID - The invention relates to a microcrystalline form of a compound which is an inhibitor of PGD | 2010-02-18 |
20100041700 | Substituted 1-(Azolin-2-yl)-Amino-1,2-Heterocyclyl-Ethane Compounds For Combating Pests - The present invention relates to 1-(Azolin-2-yl)-amino-1,2-heterocyclyl-ethane compounds, which are useful for combating insects, arachnids and nematodes. The present invention also relates to methods for combating animal pests and to compositions for combating animal pests. It has been found that animal pests can be combated by 1-(Azolin-2-yl)-amino-1,2-heterocyclyl-ethane compounds of the general formula (I): wherein A is a radical of the formulae A | 2010-02-18 |
20100041701 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS - The invention provides compounds of formula I: | 2010-02-18 |
20100041702 | BENZIMIDAZOLE CANNABINOID AGONISTS - The present invention is related to novel benzimidazole compounds of Formula (I) having cannabinoid receptor agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals, in particular humans. | 2010-02-18 |
20100041703 | RAPID DISINTEGRATION MONOLAYER FILM FOR THE ORAL ADMINISTRATION OF ACTIVE SUBSTANCES - Rapid-disintegration monolayer film for the oral administration of active substances, comprising a water-soluble support containing at least one active substance, characterized in that it comprises a polymeric mixture of a hydrophilic film-forming agent formed from a copolymer of polyvinyl alcohol and of polyethylene glycol (PVA-PEG), of an active substance and of a hydrophilic gelling agent. | 2010-02-18 |
20100041704 | DERMAL COMPOSITIONS OF SUBSTITUTED AMIDES AND THE USE THEREOF AS MEDICATION FOR PAIN AND PRURITUS - Dermal compositions comprising topical formulations of bupivacaine or ropivacaine, characterized by effective dermal absorption and long duration of dermal anesthetic activity, and intended for use in patients suffering from pruritus and dermal pain, including neuropathic pain, are provided. Compositions containing both bupivacaine and capsaicin are provided. Methods of alleviating pain by the topically administration of these compounds are also provided. | 2010-02-18 |
20100041705 | Organic Compounds - The present invention provides a compound of formula (I): | 2010-02-18 |
20100041706 | Compounds 501 - The present invention relates to a novel crystalline form of 4-(5-{( | 2010-02-18 |
20100041707 | INHIBITORS OF ION CHANNELS - Compounds, compositions and methods are provided which are useful in the treatment of diseases through the inhibition of sodium ion flux through voltage-gated sodium channels. More particularly, the invention provides heterocyclic aryl sulfonamides, compositions and methods that are useful in the treatment of central or peripheral nervous system disorders, particularly pain and chronic pain by blocking sodium channels associated with the onset or recurrence of the indicated conditions. The compounds, compositions and methods of the present invention are of particular use for treating neuropathic or inflammatory pain by the inhibition of ion flux through a voltage-gated sodium channel. | 2010-02-18 |
20100041708 | N-PHENYLARYLSULFONAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING THE COMPOUND AS ACTIVE INGREDIENT, SYNTHETIC INTERMEDIATE FOR THE COMPOUND AND PROCESS FOR IT'S PREPARATION - An N-phenylarylsulfonylamide compound of formula (I) | 2010-02-18 |
20100041709 | SUBSTITUTED N-(4-CYANO-1H-PYRAZOL-3-YL)METHYLAMINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF - The present invention relates to compounds corresponding to formula (I): | 2010-02-18 |
20100041710 | PENETRATION ENHANCER FOR INSECTICIDES - Methods for enhancing penetration of agrochemical active substances through the cuticle of a plant are disclosed. Also disclosed are compositions comprising at least one penetration enhancer. | 2010-02-18 |
20100041711 | Urea Glucokinase Activators - This application relates to novel urea glucokinase activators and use of the compounds of the invention for preparation of a medicament for the treatment of various diseases, e.g. for the treatment of type 2 diabetes. Further encompassed is a pharmaceutical composition comprising a compound according to the invention and a process for preparing such. | 2010-02-18 |
20100041712 | SUBSTITUTED IMIDAZOLE COMBINATIONS - This invention relates to a composition comprising a combination of a) an alpha substituted 2-benzyl substituted imidazole and b) a 1-N-arylpyrazole, and optionally c) an insect growth regulator, and their use as a parasiticide in mammals. | 2010-02-18 |
20100041713 | SUBSTITUTED AMINOTETRALINES - The invention is concerned with the compounds of formula I: | 2010-02-18 |
20100041714 | BI-ARYL AMINOTETRALINES - The invention is concerned with the compounds of formula I: | 2010-02-18 |
20100041715 | SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONISTS AND METHODS FOR USE THEREOF - The invention provides certain well-defined benzamides that are useful as sphingosine-1-phosphate antagonists. As such, the compounds described herein are useful in treating a wide variety of disorders associated with modulation of sphingosine-1-phosphate receptors. | 2010-02-18 |
20100041716 | NITROXIDES FOR USE IN TREATING OR PREVENTING HYPERCHOLESTEROLEMIA - Pharmaceutical compositions are provided that are useful in treating hypercholesterolemia. The compositions comprise a pharmaceutically acceptable carrier, and an effective therapeutic or prophylactic amount of a nitroxide antioxidant that alters the expression of one or more genes related to hypercholesterolemia. Methods are also provided for the use of the pharmaceutical compositions in the treatment or prevention of hypercholesterolemia. In a preferred embodiment, the nitroxide antioxidant is Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl). | 2010-02-18 |
20100041717 | N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES - Compounds of formula (Ia) and (Ib), wherein A, B, C, R | 2010-02-18 |
20100041718 | PESTICIDAL COMPOSITIONS - A pesticidal composition comprising a pesticide, an ammonium salt, and a nonionic surfactant, is provided. | 2010-02-18 |
20100041719 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF - This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment of various disorders. | 2010-02-18 |
20100041720 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS - Disclosed herein are cannabinoid receptor ligands of formula (I) | 2010-02-18 |
20100041721 | SELECTIVE ANDROGEN RECEPTOR MODULATORS - This invention provides compounds of formulas I, Ia, Ib, Ic, Id, Ie, If or Ig or salts thereof, pharmaceutical compositions comprising a compound of formulas I, Ia, Ib, Ic, Id, Ie, If or Ig and a pharmaceutically acceptable excipient, methods of modulating the androgen receptor, methods of treating diseases beneficially treated by an androgen receptor modulator (e.g., sarcopenia, prostate cancer, contraception, type 2 diabetes related disorders or diseases, anemia, depression, and renal disease) and processes for making compounds of formulas I, Ia, Ib, Ic, Id, Ie, If or Ig and intermediates useful in the preparation of same. | 2010-02-18 |
20100041722 | ORGANIC COMPOUNDS - The present invention provides a compound of formula I: | 2010-02-18 |
20100041723 | Thiazole Compound (as PPAR delta) Ligand and Pharmaceutical, Cosmetic and Health Food Comprised Thereof - The present invention relates to a thiazole compound as a peroxisome proliferator activated receptor δ (PPARδ) activator or pharmaceutically acceptable salts thereof, and a pharmaceutical composition, a functional cosmetic composition, a health food, health beverages, a food additive and animal feeds containing the same. | 2010-02-18 |
20100041724 | Process For Synthesizing A CETP Inhibitor - An efficient process is disclosed for producing a compound that is an inhibitor of CETP. The last step of the process is the coupling of an oxazolidinone derivative with a biphenyl moiety to provide a compound of formula (I). In a specific embodiment of this synthesis, a crystalline product is produced which is characterized as a non-solvated crystalline polymorph. | 2010-02-18 |
20100041725 | STABLE PHARMACEUTICAL COMPOSITION - A pharmaceutical composition comprising a compound represented by the general formula (I): | 2010-02-18 |
20100041726 | INHIBITORS OF Akt ACTIVITY - Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis. | 2010-02-18 |
20100041727 | Crystalline Modification of Fipronil - The present invention relates to a crystalline modification of fipronil, to process for the preparation of the same, to pesticidal and parasiticidal mixtures and compositions comprising said crystalline modification and to their use for combating pests and parasites. | 2010-02-18 |
20100041728 | HCV INHIBITING MACROCYCLIC PHENYLCARBAMATES - Compounds of the formula 1: | 2010-02-18 |
20100041729 | DITHIOLOPYRROLONES COMPOUNDS AND THEIR THERAPEUTIC APPLICATIONS - The present invention provides dithiolopyrrolone compounds of the general formula I, and their salts, wherein A is sulfur or carbon, and R | 2010-02-18 |
20100041730 | ALKYLATED HETEROCYCLIC REACTION PRODUCTS USEFUL AS ANTIOXIDANTS - This invention relates to novel macromolecular compositions having oxidation inhibition characteristics that are exhibited when added to organic material normally susceptible to oxidative degradation in the presence of air or oxygen, such a petroleum products, synthetic polymers, and elastomeric substances. | 2010-02-18 |
20100041731 | SOLID STATES OF ATORVASTATIN POTASSIUM - Atorvastatin potassium crystalline Forms A, B, E, F, and G are provided. Also provided are methods of preparing atorvastatin potassium crystalline Forms A, B, E, F, and G. Atorvastatin potassium crystalline Forms A, B, E, F, and G may be used to prepare pharmaceutical compositions useful for the treatment of hypercholesterolemia or hyperlipidemia. | 2010-02-18 |
20100041732 | METHODS FOR IDENTIFYING COMPOUNDS THAT INHIBIT HIV INFECTION - This invention provides novel methods for identifying agents that inhibit HIV infection. The anti-HIV agents are identified by screening test compounds for ability to down-regulate the kinase activity or the expression of a PAK3 molecule. Such PAK3 modulators can be further examined for their activity in inhibiting HIV infection. These novel anti-HIV agents are useful in the prevention or treatment of HIV infection and conditions associated with HIV infection. | 2010-02-18 |
20100041733 | NOVEL RNAi THERAPEUTIC FOR TREATMENT OF HEPATITIS C INFECTION - Small interfering RNAs (siRNAs) or small hairpin RNA (shRNAs) and compositions comprising same are provided that specifically target human cyclophilin A (CyPA) to effectively inhibit Hepatitis C(HCV) infection in a cell. Such siRNA and shRNAs may have a length of from about 19 to about 29 contiguous nucleotides corresponding to a specific region of human cyclophilin A (CyPA) cDNA of from about nucleotide 155 to about nucleotide 183 having particular potency against CyPA and HCV. Such siRNA and shRNAs may be formulated as naked compositions or as pharmaceutical compositions. DNA polynucleotides, plasmids, and viral or non-viral vectors are also provided that encode siRNA or shRNA molecules, which may be delivered directly to cells or in combination with known delivery agents, such as lipids, polymers, encapsulated lipid particles, such as liposomes. Methods for treating, managing inhibiting, preventing, etc., HCV infection using such siRNA and shRNAs and compositions comprising same are also provided. | 2010-02-18 |
20100041734 | MODULATION OF TOLL-LIKE RECEPTOR 7 EXPRESSION BY ANTISENSE OLIGONUCLEOTIDES - Antisense oligonucleotide compounds, compositions and methods are provided for down regulating the expression of TLR7. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding TLR7. The compositions may also comprise antisense oligonucleotides targeted to nucleic acids encoding TLR7 in combination with other therapeutic and/or prophylactic compounds and/or compositions. Methods of using these compounds and compositions for down-regulating TLR7 expression and for prevention or treatment of diseases wherein modulation of TLR7 expression would be beneficial are provided. | 2010-02-18 |
20100041735 | MODULATION OF TOLL-LIKE RECEPTOR 3 EXPRESSION BY ANTISENSE OLIGONUCLEOTIDES - Antisense oligonucleotide compounds, compositions and methods are provided for down regulating the expression of TLR3. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding TLR3. The compositions may also comprise antisense oligonucleotides targeted to nucleic acids encoding TLR3 in combination with other therapeutic and/or prophylactic compounds and/or compositions. Methods of using these compounds and compositions for down-regulating TLR3 expression and for prevention or treatment of diseases wherein modulation of TLR3 expression would be beneficial are provided. | 2010-02-18 |
20100041736 | Isolated MCPIP and Methods of Use - A monocyte chemoattractant protein (MCP-1)-inducible protein, MCPIP, its polynucleotide and amino acid sequences from mouse and human, and methods for its use are disclosed. | 2010-02-18 |
20100041737 | Gene Vector - A gene vector comprising a miRNA sequence target. | 2010-02-18 |
20100041738 | HYBRIDIZATION-STABILIZING CONSTRUCT - A Z-shaped construct having the capacity to hybridize to double stranded DNA in a trans fashion to affect transcription is produced from at least two oligonucleotides, connected to each other, wherein the oligonucleotides are connected to one another through one of sequence specific Watson-Crick base pairing; a covalent linker or a covalent bond directly between the backbones or the bases of said oligonucleotides; or a non-covalent linker or a non-covalent bond directly between the backbones or the bases of said oligonucleotides. | 2010-02-18 |
20100041739 | Transfection Reagent - The present invention relates to a polyalkyleneimine polymer having a repeat unit comprising a hydrophilic group, agents containing the same and methods for their use. | 2010-02-18 |
20100041740 | FLU VACCINES AND METHODS OF USE THEREOF - This disclosure is directed, inter alia, to polynucleotides, polypeptides, vectors, cells and compositions comprising the same, and their use in affecting viral pathogenesis, in particular for influenza viral infection. | 2010-02-18 |
20100041741 | SUPPRESSION OF MITOCHONDRIAL OXIDATIVE STRESS - Compositions for suppressing and inhibiting mitochondrial oxidative stress. The compositions include a human mitochondrial superoxide dismutase (SOD2) gene. Methods of treating patients suffering from diseases or disorders associated with mitochondrial oxidative stress. | 2010-02-18 |
20100041742 | RIBOSWITCHES, METHODS FOR THEIR USE, AND COMPOSITIONS FOR USE WITH RIBOSWITCHES - It has been discovered that certain natural mRNAs serve as metabolite-sensitive genetic switches wherein the RNA directly binds a small organic molecule. This binding process changes the conformation of the mRNA, which causes a change in gene expression by a variety of different mechanisms. Modified versions of these natural “riboswitches” (created by using various nucleic acid engineering strategies) can be employed as designer genetic switches that are controlled by specific effector compounds. Such effector compounds that activate a riboswitch are referred to herein as trigger molecules. The natural switches are targets for antibiotics and other small molecule therapies. In addition, the architecture of riboswitches allows actual pieces of the natural switches to be used to construct new non-immunogenic genetic control elements, for example the aptamer (molecular recognition) domain can be swapped with other non-natural aptamers (or otherwise modified) such that the new recognition domain causes genetic modulation with user-defined effector compounds. The changed switches become part of a therapy regimen-turning on, or off, or regulating protein synthesis. Newly constructed genetic regulation networks can be applied in such areas as living biosensors, metabolic engineering of organisms, and in advanced forms of gene therapy treatments. | 2010-02-18 |
20100041743 | TRANSGENIC ANIMAL WITH ENHANCED IMMUNE RESPONSE AND METHOD FOR THE PREPARATION THEREOF - The present invention provides a method for producing a transgenic (Tg) non-human animal capable of developing an enhanced humoral immune response against an antigen as compared to a non-transgenic control animal of the same species, comprising introducing into said non-human animal a genetic construct providing for enhanced MHC class I-related neonatal Fc receptor (FcRn) activity. Also provided a Tg non-human animal comprising a genetic construct providing for enhanced FcRn activity, as well as the use of such animal in a non-therapeutical method. Therapeutic genetic constructs and methods are also provided. The present invention further provides methods for producing immunoglobulins. | 2010-02-18 |
20100041744 | OILY PACLITAXEL COMPOSITION AND FORMULATION FOR CHEMOEMBOLIZATION AND PREPARATION METHOD THEREOF - Oily paclitaxel composition and formulation for chemoembolization and preparation method thereof solubilizing paclitaxel in an oily contrast medium. The composition of the present invention solubilizes paclitaxel and has an advantage of delivering anticancer drug to the target cells by chemoembolization since it is possible to visualize the blood vessel during the chemoembolization process. The present invention also relates to oily paclitaxel composition and formulation additionally comprising chemicals that prevent paclitaxel precipitation for prolonged preservation and the preparation method thereof. Since the composition of the present invention solubilize paclitaxel effectively and can be visualized during chemoembolization, it can be used for TACE to treat hepatoma and other solid tumors. | 2010-02-18 |
20100041745 | Aigialomycin D and Derivatives Thereof and Their Use in Treating Cancer or Malaria or a Microbial Infection - The invention describes a process for making compound (2), comprising the step of cyclising diene (3). Compound (2) may be aigialomycin D or a derivative thereof or may be elaborated to make aigialomycin D or derivative thereof. Furthermore compound (2) or derivative thereof can be used in treating cancer or malaria or a microbial infection. | 2010-02-18 |
20100041746 | NOVEL USE OF ORGANIC COMPOUNDS - The present invention refers to compounds of the general formulae Ia to Ie as defined above for use as/in a composition (especially foods and dietary supplements, cosmetic, as well as pharmaceutical compositions) for the prevention and improvement of muscular disorders and for the improvement of muscle function. Other fields of use are disorders connected to impaired lipid metabolism, impaired glucose metabolism and impaired insulin action, obesity, overweight conditions, eating disorders such as bulimia and anorexia nervosa, cardiovascular diseases, atherosclerosis, vascular diseases, heart failure, inflammatory disorders such as arthritis, rheumatoid arthritis, osteoarthritis, gout, gastrointestinal disorders such as inflammatory bowel syndrome, Crohn's disease, gastritis, irritable bowel syndrome and ulcerative colitis, skin related conditions such as psoriasis, eczema, burns, dermatitis, and allergy, respiratory disorders such as asthma, chronic obstructive pulmonary disease (COPD), allergic diseases, and/or bone disorders such as osteoporosis and osteopenia. The compounds may also be used for bodyshaping, for improving the muscle:fat ratio or for accelerating skin wound healing. The present invention is also directed to dietary compositions such as (fortified) food, beverages, (fortified) feed, food additives, beverage additives, feed additives, clinical nutrition, dietary supplements, functional food, functional feed and nutraceuticals and to pharmaceutical compositions containing such compounds, to methods of treating the above mentioned disorders/diseases in mammals including humans and to the compounds of the formula I themselves. Another object of the present invention is the use of such compounds for the manufacture of a composition for the treatment of such disorders/diseases as mentioned above. | 2010-02-18 |
20100041747 | USE OF CERTAIN CHEMICAL COMPOUNDS FOR THE INHIBITION OF THE PEPTIDYL-PROLYL CIS/TRANS ISOMERASE ACTIVITY OF CYCLOPHILINS - The present invention relates to the use of certain spiro, ketone and carboxylic acid compounds for the inhibition of the peptidyl-prolyl cis/trans isomerase activity of cyclophilins and the use of these compounds for the production of a cosmetic or pharmaceutical composition for the promotion of hair growth or for the treatment or prevention of inflammatory autoimmune diseases, of diseases caused by fungi, of bacterial infections, of viral infections, of diseases caused by parasites, protozoa or worms, of cancer, of diseases of cells, of fibrosing diseases, and of non-neoplastic changes and diseases which are attributable to prions and changes in the structure and function of cellular proteins and cells. | 2010-02-18 |
20100041748 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES - The invention relates to Fatty Acid Acetylated Salicylate Derivatives; compositions comprising an effective amount of a Fatty Acid Acetylated Salicylate Derivative; and methods for treating or preventing an inflammatory disorder comprising the administration of an effective amount of a Fatty Acid Acetylated Salicylate Derivative. | 2010-02-18 |
20100041749 | Organo-Arsenoxide Compounds and Use Thereof - The present invention relates to organo-arsenoxide compounds and to methods for their synthesis. The invention also relates to pharmaceutical compositions comprising these compounds and to their use in the treatment of diseases and disorders, in particular proliferative diseases and disorders, including treatment of solid tumors and leukaemia. | 2010-02-18 |
20100041750 | Ester Compound and Use Thereof - A compound represented by the formula (I): | 2010-02-18 |
20100041751 | Method to Reduce Oxidative Damage and Improve Mitochondrial Efficiency - Methods for the reduction of mitochondrial oxidative damage and improved mitochondrial efficiency in an animal by administration of medium chain triglycerides or prodrug of medium chain triglycerides to the animal are provided. | 2010-02-18 |
20100041752 | Production of peracids using an enzyme having perhydrolysis activity - A method is provided for producing peroxycarboxylic acids from carboxylic acid esters. More specifically, carboxylic acid esters are reacted with an inorganic peroxide, such as hydrogen peroxide, in the presence of an enzyme catalyst having perhydrolysis activity derived from | 2010-02-18 |
20100041753 | INHIBITION OF BIOFILM FORMATION - The present invention relates to compositions and methods for reducing or inhibiting biofilm comprising modulating expression of a cysB gene in a cell. The invention also provides methods for modulating the expression of a cysB, cysD, cysI, cysJ, cysK, and ybiK. The invention further provides methods for identifying gene(s) involved in biofilm formation and for identifying biofilm inhibitors. | 2010-02-18 |
20100041754 | Novel natural oil gels and their application - The invention is an article of manufacture, comprising a blend of: (A) from 1 to 50 weight percent of at least one block copolymer, wherein the block copolymer has at least one polystyrene block and at least one unsaturated rubber segment; and (B) from 99 to 50 weight percent of a natural oil. The natural oil of this invention is of natural animal, plant or vegetable oils or mixtures thereof, and the block copolymers have a polystyrene block and a rubber block where the rubber blocks are unsaturated rubbers such as polyisoprene, polybutadiene, or mixtures thereof. The block copolymers useful for the present invention are triblock polymers, radial (star) polymers, multiblock polymers, diblock polymers, or mixtures thereof. | 2010-02-18 |
20100041755 | FATTY ACID TREATMENT FOR CARDIAC PATIENTS - A method of treating patients in need of treatment for a cardiac disorder has been found which comprises administering to the patient a seven carbon fatty acid compound or derivative thereof, wherein the compound or derivative thereof is able to readily enter the mitochondrion without special transport enzymes. A dietary formulation suitable for treatment of heart tissue in cardiac or surgical patients has been found which comprises a seven-carbon fatty acid chain, wherein the seven-carbon fatty acid chain is characterized by the ability to transverse the inner mitochondrial membrane by a transport mechanism which does not require carnitine palmitoyltransferase I, carnitine palmitoyltransferase II, or carnitine/acylcarnitine translocase and the ability to undergo mitochondrial β-oxidation, and wherein the compound is selected from the group consisting of n-heptanoic acid or a derivative thereof, a triglyceride comprising n-heptanoic acid or a derivative thereof, and triheptanoin or a derivative thereof. | 2010-02-18 |
20100041756 | METHOD OF MODULATING B CELL FUNCTIONING - The present invention relates generally to a method of modulating cellular functioning. More particularly, the present invention relates to a method of modulating B cell functioning, for example B cell proliferation, utilising an IDO-mediated tryptophan metabolite as herein defined (particular examples of such IDO-mediated tryptophan metabolites include 3-hydroxykynurenic acid, 3-hydroxyanthranilic acid, picolinic acid, quinolinic acid and tranilast). The method of the present invention is useful, inter alia, in the treatment and/or prophylaxis of conditions characterised by aberrant, unwanted or otherwise inappropriate B cell functioning such as antibody production, autoimmune conditions and B cell proliferation and neoplasias. In a related aspect, the present invention is directed to a method of therapeutically and/or prophylactically treating rheumatoid arthritis via the administration of the above-mentioned compounds. | 2010-02-18 |
20100041757 | N-ARYL-HYDROXYALKYLIDENE-CARBOXAMIDE COMPOUNDS AND THEIR USE - This disclosure generally relates to chemicals that affect sensory processes. More particularly, this present invention relates to peripheral sensory compounds (including, e.g., 2-Isopropyl-5-methyl-cyclohexanecarboxylic acid [2′-hydroxy-2′-(3″-hydroxy-phenyl)-ethyl]-N-methyl-amide) that are useful in sensory refreshment, inhibit the perception of itch and pain, and alleviation of skin irritation, itch, and pain. These compositions have surprising pharmacokinetic properties that allow a prolonged duration of pharmacological actions and may be administered topically or systemically. | 2010-02-18 |
20100041758 | ADHESIVE PREPARATION - An adhesive preparation which has a pressure-sensitive adhesive layer comprising two components, i.e., a C1-4 alcohol ester of 4-{[2-((1R,2R,3R)-3-hydroxy-2-{(1E,3S)-3-hydroxy-4-[3-(methoxymethyl)phenyl]but-1-enyl}-5-osocyclopentyl)ethyl]sulfanyl}butanoic acid and a silicone-based pressure-sensitive adhesive. This is an effective and safe preparation which is stable, shows little change in skin permability and release a drug not rapidly but continuously. | 2010-02-18 |
20100041759 | MULTI-PHASE RELEASE POTASSIUM GUAIACOLSULFONATE COMPOSITIONS - Formulations have been developed administering a guaiacolsulfonate salt, preferably potassium salt, in multi-phases. In a preferred embodiment, the formulation contains potassium guaiacolsulfonate in an immediate release (“IR”) form and a sustained or delayed release (“DR”) form and/or pulsed release (“PR”) form. In another embodiment, the potassium guaiacolsulfonate is released in a gradient, decreasing the side effects associated with rapidly elevated blood levels. In another embodiment, the drug is bound to an ion-exchange resin, which can be suspended in a liquid or incorporated into a matrix for delayed, sustained and/or pulsed release. Dosage unit forms may be tablets, gels, liquids, capsules, beads, microparticles, films or lozenges. Multi-phase delivery can also be achieved through the use of a kit that provides for dosage escalation. The formulations are useful in the treatment of one or more symptoms of coughs, colds, sinusitis and other respiratory illnesses. The formulations are also useful in the treatment or relief of fibromyalgia, pain, and Irritable Bowel Syndrome. | 2010-02-18 |
20100041760 | MONOARYL AMINOTETRALINES - The invention is concerned with the compounds of formula I: | 2010-02-18 |
20100041761 | NEW HALO ACTIVE AROMATIC SULFONAMIDE ORGANIC COMPOUNDS AND ODOR CONTROL USES THEREFOR - Aromatic N-halosulfonamide organic compounds have been known for over one hundred years. The ability of these compounds to release active halogen ions has been utilized in a range of biocidal and fungicidal applications. The most widely used halogen sulfonamide organic compound for these applications is Chloramine-T. This invention deals with the new use of discovered compositions of matter, halo active aromatic sulfonamide organic compounds and use of solutions of these compounds as, odor control agents. The odor control solutions may be buffered to a predetermined pH. The odor control compositions may further incorporate small percentages of low molecular weight alcohols and wetting agents. | 2010-02-18 |
20100041762 | SUBSTITUTED FUSED-RING COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES - The invention relates to compounds of structural formula (I) or (II): | 2010-02-18 |
20100041763 | Salicylamide derivatives as nicotinic alpha 7 modulators - The application discloses compounds of Formula I: | 2010-02-18 |
20100041764 | THERAPEUTIC AGENT FOR DIABETIC NEUROPATHY - A therapeutic agent for the treatment of diabetic neuropathy which comprises (±)-[2-[4-(3-ethoxy-2-hydroxypropoxy)phenylcarbamoyl]-ethyl]dimethylsulfonium p-toluenesulfonate of the formula (1) as an active ingredient. | 2010-02-18 |
20100041765 | HIGH CONCENTRATION LOCAL ANESTHETIC FORMULATIONS - A transdermal topical anesthetic formulation, which can be used to ameliorate or inhibit pain, has been developed. In the preferred embodiment, the topical anesthetic is a local anesthetic such as lidocaine, most preferably lidocaine free-base in a gel, and the dosage of the local anesthetic is effective in the painful area or immediately adjacent areas, to ameliorate or eliminate the pain. High concentration of local anesthetic in solution in the carrier is used to drive rapid release and uptake of the drug. Relief is typically obtained for a period of several hours. | 2010-02-18 |